Clinical Study Assessing a New Scale to Measure Onset of Action in Generalized Anxiety Disorder
NCT00715039
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Primary Diagnosis of GAD (DSM IV, 300.02) as established by the clinician using all sources of data including the MINI structured interview
- HAM A score ³20 at the Screening (Study Day -7) and Baseline (Study Day 1) Visits by observer rating
- Good health as determined by medical history, physical examination, vital signs, electrocardiography (ECG), and clinical laboratory measurements
- Covi Anxiety Scale total score ³9 and Raskin Depression Scale total score £7 at the Screening Visit (to ensure predominance of anxiety symptoms over depression symptoms)
- Age 18 to 65 (inclusive)
- Patients with most other current DSM-IV Axis I disorders.
- Patients with current or past schizophrenia, Psychotic disorder
- Delirium, dementia, amnestic, and other clinically significant cognitive disorders
- Bipolar or schizoaffective disorder
- Benzodiazepine abuse or dependence; and/or Factitious disorder.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Los Angeles, California
- Glendale, California
- Northridge, California
- Orange, California
- San Diego, California
- Sherman Oaks, California
- Van Nuys, California
- Casselberry, Florida
- Orlando, Florida
- Atlanta, Georgia
- Marietta, Georgia
- Overland Park, Kansas
- Overland Park, Kansas
- Albuquerque, New Mexico
- Albuquerque, New Mexico
- Cincinnati, Ohio
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | Clinical Study Assessing a New Scale to Measure Onset of Action in Generalized Anxiety Disorder | |||
Official Title ICMJE | A 4-Week, Double-Blind, Randomized, Multicenter, Fixed Dose, Placebo-Controlled, Parallel Group Study of Lorazepam and Paroxetine in Patients With Generalized Anxiety Disorder: Assessment of a New Instrument Intended to Capture Rapid Onset | |||
Brief Summary | The study is to assess the performance characteristics of a new measure to assess onset of efficacy in a GAD patient population. | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Not Applicable | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Care Provider, Investigator) Primary Purpose: Basic Science | |||
Condition ICMJE | Anxiety Disorders | |||
Intervention ICMJE |
| |||
Study Arms ICMJE |
| |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Actual Enrollment ICMJE | 169 | |||
Original Actual Enrollment ICMJE | Same as current | |||
Actual Study Completion Date ICMJE | May 2004 | |||
Primary Completion Date | Not Provided | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years to 65 Years (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | United States | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00715039 | |||
Other Study ID Numbers ICMJE | A9001141 | |||
Has Data Monitoring Committee | No | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Director, Clinical Trial Disclosure Group, Pfizer, Inc. | |||
Study Sponsor ICMJE | Pfizer | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | October 2008 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |